ImmuneHuman RCT
Larazotide: what happened to the coeliac drug that reached Phase 3
Five controlled coeliac trials, one small positive signal at the lowest dose, and a Phase 3 stopped in 2022 because it wasn't going to work.
Larazotide
An oral tight-junction peptide tested in hundreds of coeliac patients; its Phase 3 trial was stopped in 2022 after an interim look.
- Also known as
- Larazotide acetate, AT-1001, AT1001
- Area
- Immune
- Status
- Not approved; Phase 3 coeliac trial terminated early in 2022